BiotechTube

Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)

ApprovedUNKNOWN
2 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Crohn Disease

Conditions

Crohn Disease

Trial Timeline

Dec 21, 2021 → Jun 15, 2024

NCT ID
NCT05072782

About Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)

Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate) is a approved stage product being developed by Celltrion for Crohn Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT05072782. Target conditions include Crohn Disease.

What happened to similar drugs?

11 of 20 similar drugs in Crohn Disease were approved

Approved (11) Terminated (4) Active (9)
✅MirikizumabEli LillyApproved
✅Adalimumab Injection + ThiopurineAbbVieApproved
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Infliximab + Prednisolone + AzathioprinePfizerApproved
✅Celebrex + placeboPfizerApproved
✅Cimzia + MesalamineUCBApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05072782ApprovedUNKNOWN

Competing Products

20 competing products in Crohn Disease

See all competitors
ProductCompanyStageHype Score
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
21
LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)Eli LillyPhase 2
42
CT-P13 + RemicadeCelltrionPhase 3
40
Ustekinumab 45 mg + Ustekinumab 90 mgCelltrionPre-clinical
33
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
CP-461Astellas PharmaPhase 2
35
UstekinumabSun PharmaceuticalPre-clinical
33
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumab + adalimumab + placeboEisaiPhase 2/3
38
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35
MirikizumabEli LillyPhase 3
44